Endocrinology

Your Article Summary

See Latest Articles

Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
Therapeutics and Clinical Risk Management, 09/29/09

Iwamoto J et al. – The present study evaluated the outcome of treatment with ALN for 5 years in postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures. ALN successfully suppressed bone turnover and sustained the metacarpal BMD over the 5–year period of treatment in postmenopausal Japanese women with an increased risk of fractures.

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

Severe exfoliative dermatitis caused by strontium ranelate: two cases of a new drug reaction
Age and Aging, 03/19/10

Repair in osteonecrosis of the femoral head: MR imaging features at long-term follow-up
Clinical Rheumatology, 03/18/10

Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia
Archives of Medical Science, 03/18/10

 See all of Bone Metabolism

Today in Pharmacology/kinetics...keeping you current

Receive free subspecialty "5-minute updates" via email

A review of the effect of anticonvulsant medications on bone mineral density and fracture risk
The American Journal of Geriatric Pharmacotherapy, 03/19/10

Peroxisome Proliferator-Activated Receptor- Genotype Influences Metabolic Phenotype and May Influence Lipid Response to Statin Therapy in Humans: A Genetics of Diabetes Audit and Research Tayside Study
Journal of Clinical Endocrinology and Metabolism, 03/19/10

Modulatory Effect of Raloxifene and Estrogen on the Metabolic Action of Growth Hormone in Hypopituitary Women
Journal of Clinical Endocrinology and Metabolism, 03/19/10

 See all of Pharmacology/kinetics